About Claris Bio
Claris Bio is a company based in Jersey City (United States) founded in 2018 by Sunil Chauhan, Clarke Atwell, and Reza Dana. It operates as a HealthTech. Claris Bio has raised $280.5 million across 5 funding rounds from investors including RA Capital, Novo Holdings and Mass General Brigham Ventures. Claris Bio offers products and services including CSB-001. Claris Bio operates in a competitive market with competitors including Ilya Pharma, QBiotics, MediWound, Aurion Biotech and Resolution Therapeutics, among others.
- Headquarter Jersey City, United States
- Founders Sunil Chauhan, Clarke Atwell, Reza Dana
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Claris Biotherapeutics
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$280.5 M (USD)
in 5 rounds
-
Latest Funding Round
$118 M (USD), Series B
Jul 28, 2026
-
Investors
RA Capital
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Claris Bio
Claris Bio offers a comprehensive portfolio of products and services, including CSB-001.
A topical solution for corneal integrity restoration developed.
Funding Insights of Claris Bio
Claris Bio has successfully raised a total of $280.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $118 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Claris Bio
Claris Bio has secured backing from 11 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include RA Capital, Novo Holdings and Mass General Brigham Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Claris Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Claris Bio
Investment portfolio details for Claris Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Claris Bio
Detailed financials for Claris Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Claris Bio Comparisons
Peer comparison for Claris Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Claris Bio
Claris Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ilya Pharma, QBiotics, MediWound, Aurion Biotech and Resolution Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Enzymatic therapies for tissue repair and regeneration are developed.
|
|
| Locked | Locked | Locked |
Aurion Biotech is focused on developing advanced therapies for ocular diseases.
|
|
| Locked | Locked | Locked |
Macrophage cell therapies are developed for inflammatory and liver diseases.
|
|
| Locked | Locked | Locked |
Noninvasive devices and biologics for wound healing are developed.
|
Detailed competitors of Claris Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Claris Bio
Complete news archive for Claris Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Claris Bio
Claris Bio was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Claris Bio is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
Clarke Atwell is the current CEO of Claris Bio. They have also founded this company.
Claris Bio is a funded company, having raised a total of $280.5M across 5 funding rounds to date.
Claris Bio is engaged in advancing corneal therapy through innovative biologic solutions. The company operates in the ophthalmology sector, targeting unmet medical needs with a focus on conditions like Limbal Stem Cell Deficiency (LCSD). Their lead program, CSB-001, is developed as a topical ocular biologic using hepatocyte growth factor (HGF) to restore structural and functional corneal integrity. Research and development efforts are supported by robust scientific data and partnerships with institutions like Massachusetts Eye and Ear Infirmary.
Claris Bio's top competitors include Ilya Pharma, Aurion Biotech and SanuWave.
Claris Bio offers CSB-001.
Claris Bio has 11 investors. Key investors include RA Capital, Novo Holdings, Mass General Brigham Ventures, Janus Henderson, and Samsara BioCapital.